Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Oncternal Therapeutics, Inc. | Financial_Report.xls |
| EX-23.1 - EX-23.1 - Oncternal Therapeutics, Inc. | d305905dex231.htm |
| EX-31.1 - EX-31.1 - Oncternal Therapeutics, Inc. | d305905dex311.htm |
| EX-32.2 - EX-32.2 - Oncternal Therapeutics, Inc. | d305905dex322.htm |
| EX-31.2 - EX-31.2 - Oncternal Therapeutics, Inc. | d305905dex312.htm |
| EX-32.1 - EX-32.1 - Oncternal Therapeutics, Inc. | d305905dex321.htm |
| EX-10.61 - EX-10.61 - Oncternal Therapeutics, Inc. | d305905dex1061.htm |
| 10-K - FORM 10-K - Oncternal Therapeutics, Inc. | d305905d10k.htm |
Exhibit 10.60
2012 Compensation Information for Registrant’s Executive Officers
The table below provides information regarding (i) the base salary of each executive officer of GTx, Inc. (the “Company”), effective as of January 1, 2012, and (ii) the target cash bonus award for each of the Company’s executive officers under the Company’s Executive Bonus Compensation Plan for fiscal 2012, expressed as a percentage of applicable base salary:
| Executive Officer |
Title |
2012 Annual Base Salary ($) |
2012
Target Bonus (%) |
|||||||
| Mitchell S. Steiner |
Chief Executive Officer and Vice-Chairman of the Board | 546,000 | 65 | |||||||
| Mark E. Mosteller |
Vice President, Chief Financial Officer and Treasurer | 310,006 | 30 | |||||||
| Marc S. Hanover |
President and Chief Operating Officer | 475,020 | 55 | |||||||
| Ronald A. Morton, Jr. |
Vice President, Chief Medical Officer | 470,106 | 1 | 30 | ||||||
| James T. Dalton |
Vice President, Preclinical Research and Development | 416,000 | 30 | |||||||
| Henry P. Doggrell |
Vice President, General Counsel and Secretary | 351,281 | 30 | |||||||
| 1 | Dr. Morton will also be eligible for tax gross-up payments related to certain travel expenses paid by the Company during 2012 on his behalf. |